Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease / 生理学报
Acta Physiologica Sinica
;
(6): 398-406, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-337734
ABSTRACT
There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) in the course of pathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment of T2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly. This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, the distribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Brain
/
Amyloid beta-Peptides
/
Receptors, Glucagon
/
Neuroprotective Agents
/
Therapeutic Uses
/
Diabetes Mellitus, Type 2
/
Drug Therapy
/
Glucagon-Like Peptide 1
/
Alzheimer Disease
Limits:
Animals
/
Humans
Language:
Chinese
Journal:
Acta Physiologica Sinica
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS